Philosys Healthcare Supplies Products for COVID-19 Diagnostic Kit Approval Registration

[Asia Economy Reporter Hyungsoo Park] Philosis Healthcare, which sells and its affiliate Philosis manufactures, the novel coronavirus disease (COVID-19) diagnostic kit 'Gmate COVID-19' is being recognized for its quality excellence in major countries around the world.

Philosis Healthcare announced on the 8th that since April, it has supplied products for Gmate COVID-19 approval registration worth about 1 million USD to more than 10 major countries worldwide.

The export destinations include major European countries such as Italy, Switzerland, and the United Kingdom, as well as national research institutes and ministries of health and welfare in countries like Kuwait, the United Arab Emirates, and Egypt. According to the company, they are expanding supply by sequentially obtaining key official documents proving quality excellence.

Philosis Healthcare completed clinical approval procedures at three hospitals in the United States last month and is preparing for full-scale clinical trials within the US. The application for the US Emergency Use Authorization (EUA) has also been completed.

The antigen-based Gmate COVID-19 uses saliva-based methods such as nasal mucus and sputum, making specimen collection simple and requiring little time for test judgment. The time to obtain test results is up to 20 minutes, with accuracy of about 93% or higher, making it highly useful for mobile clinics such as drive-through testing.

A Philosis Healthcare official explained, "Gmate COVID-19 is recognized by major countries worldwide for its fast testing time and excellent accuracy," adding, "Supply is increasing due to the issuance of official documents proving quality excellence."

This content was produced with the assistance of AI translation services.